Table 1.
Baseline characteristics of patients with LB and non-LB and independent risk factors for the pregnancy results.
| projects | LB group (n=1549) | non-LB group (n=5031) | t/x2 value | P value |
|---|---|---|---|---|
| Age (years) | 31.35 ± 4.53 | 36.29 ± 6.28 | -28.72 | <0.001 |
| Primary infertility | 52.2 (810/1549) | 67.1 (3374/5031) | 111.62 | <0.001 |
| Infertility years | 4.07 ± 2.92 | 5.03 ± 4.24 | -8.11 | <0.001 |
| BMI (Kg/M2) | 22.67 ± 3.11 | 23.15 ± 4.51 | -3.91 | <0.001 |
| Basal FSH (IU/L) | 11.60 ± 4.19 | 9.52 ± 5.60 | 0.89 | 0.369 |
| Basal LH (IU/L) | 5.71 ± 5.15 | 5.70 ± 5.04 | 0.10 | 0.920 |
| Basal E2 (ng/L) | 102.53 ± 451.62 | 105.20 ± 420.77 | -0.21 | 0.832 |
| Basal P (μg/L) | 1.29 ± 0.640 | 0.587 ± 0.90 | 2.01 | 0.044 |
| AMH (ng/mL) | 2.98 ± 2.78 | 1.75 ± 2.17 | 18.21 | <0.001 |
| PRL (ng/L) | 20.15 ± 32.03 | 18.37 ± 25.06 | 2.24 | 0.025 |
| AFC(n) | 12.01 ± 6.55 | 7.43 ± 6.63 | 23.81 | <0.001 |
| No. Of treatment cycles | 2.00 ± 0.580 | 2.22 ± 1.30 | -6.33 | <0.001 |
| Initiation dosage of Gn used | 183.88 ± 74.69 | 224.24 ± 80.18 | -17.58 | <0.001 |
| Total dosage of Gn used | 2816.74 ± 1047.25 | 2774.77 ± 1190.36 | 1.24 | 0.213 |
| Duration of Gn used | 12.72 ± 2.545 | 11.18 ± 3.56 | 15.79 | <0.001 |
| Oocyte number | 7.49 ± 3.014 | 5.32 ± 4.46 | 17.96 | <0.001 |
| controlled ovarian hyperstimulation protocol | ||||
| Early-follicular phase GnRH-a long protocol | 78.1 (1209/1549) | 41.6 (2096/5031) | ||
| Mid-luteal phase GnRH-a long protocol | 16.3 (253/1549) | 22.5 (1128/5031) | 710.91 <0.001 | |
| GnRH antagonist protocol and others | 5.6 (87/1549) | 35.9 (1807/5031) | ||
Data are shown as means ± standard deviation or N(%). BMI, body mass index; FSH, follicular-stimulating hormone; LH, luteinizing hormone; E2, estradiol; P, progesterone; AMH, anti-Müllerian hormone; AFC, antral follicle counting; PRL, prolactin; LB, live birth; Gn, Gonadotropin.